Cargando…
Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia
To estimate the cost-effectiveness of available diagnosis alternatives for Mucosal Leishmaniasis (ML) in Colombian suspected patients. A simulation model of the disease’s natural history was built with a decision tree and Markov models. The model´s parameters were identified by systematic review and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827906/ https://www.ncbi.nlm.nih.gov/pubmed/31682606 http://dx.doi.org/10.1371/journal.pone.0224351 |
_version_ | 1783465362079088640 |
---|---|
author | Castillo-Rodríguez, Liliana Ovalle-Bracho, Clemencia Díaz-Jiménez, Diana Sánchez-Vanegas, Guillermo Muvdi-Arenas, Sandra Castañeda-Orjuela, Carlos |
author_facet | Castillo-Rodríguez, Liliana Ovalle-Bracho, Clemencia Díaz-Jiménez, Diana Sánchez-Vanegas, Guillermo Muvdi-Arenas, Sandra Castañeda-Orjuela, Carlos |
author_sort | Castillo-Rodríguez, Liliana |
collection | PubMed |
description | To estimate the cost-effectiveness of available diagnosis alternatives for Mucosal Leishmaniasis (ML) in Colombian suspected patients. A simulation model of the disease’s natural history was built with a decision tree and Markov models. The model´s parameters were identified by systematic review and validated by expert consensus. A bottom-up cost analysis to estimate the costs of diagnostic strategies and treatment per case was performed by reviewing 48 clinical records of patients diagnosed with ML. The diagnostic strategies compared were as follows: 1) no diagnosis; 2) parasite culture, biopsy, indirect immunofluorescence assay (IFA), and Montenegro skin test (MST) combined ; 3) parasite culture, biopsy, and IFA combined; 4) PCR-miniexon; and 5) PCR-kDNA. Three scenarios were modeled in patients with ML clinical suspicion, according to ML prevalence scenarios: high, medium and low. Adjusted sensitivity and specificity parameters of a combination of diagnostic tests were estimated with a discrete event simulation (DES) model. For each alternative, the costs and health outcomes were estimated. The time horizon was life expectancy, considering the average age at diagnosis of 31 years. Incremental cost-effectiveness ratios (ICERs) were calculated per Disability Life Year (DALY) avoided, and deterministic and probabilistic sensitivity analyses were performed. A threshold of willingness to pay (WTP) of three-time gross domestic product per capita (GDPpc) (US$ 15,795) and a discount rate of 3% was considered. The analysis perspective was the third payer (Health System). All costs were reported in American dollars as of 2015. PCR- kDNA was the cost-effective alternative in clinical suspicion levels: low, medium and high with ICERs of US$ 7,909.39, US$ 5,559.33 and US$ 4,458.92 per DALY avoided, respectively. ML diagnostic tests based on PCR are cost-effective strategies, regardless of the level of clinical suspicion. PCR-kDNA was the most cost-effective strategy in the competitive scenario with the parameters included in the present model. |
format | Online Article Text |
id | pubmed-6827906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-68279062019-11-12 Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia Castillo-Rodríguez, Liliana Ovalle-Bracho, Clemencia Díaz-Jiménez, Diana Sánchez-Vanegas, Guillermo Muvdi-Arenas, Sandra Castañeda-Orjuela, Carlos PLoS One Research Article To estimate the cost-effectiveness of available diagnosis alternatives for Mucosal Leishmaniasis (ML) in Colombian suspected patients. A simulation model of the disease’s natural history was built with a decision tree and Markov models. The model´s parameters were identified by systematic review and validated by expert consensus. A bottom-up cost analysis to estimate the costs of diagnostic strategies and treatment per case was performed by reviewing 48 clinical records of patients diagnosed with ML. The diagnostic strategies compared were as follows: 1) no diagnosis; 2) parasite culture, biopsy, indirect immunofluorescence assay (IFA), and Montenegro skin test (MST) combined ; 3) parasite culture, biopsy, and IFA combined; 4) PCR-miniexon; and 5) PCR-kDNA. Three scenarios were modeled in patients with ML clinical suspicion, according to ML prevalence scenarios: high, medium and low. Adjusted sensitivity and specificity parameters of a combination of diagnostic tests were estimated with a discrete event simulation (DES) model. For each alternative, the costs and health outcomes were estimated. The time horizon was life expectancy, considering the average age at diagnosis of 31 years. Incremental cost-effectiveness ratios (ICERs) were calculated per Disability Life Year (DALY) avoided, and deterministic and probabilistic sensitivity analyses were performed. A threshold of willingness to pay (WTP) of three-time gross domestic product per capita (GDPpc) (US$ 15,795) and a discount rate of 3% was considered. The analysis perspective was the third payer (Health System). All costs were reported in American dollars as of 2015. PCR- kDNA was the cost-effective alternative in clinical suspicion levels: low, medium and high with ICERs of US$ 7,909.39, US$ 5,559.33 and US$ 4,458.92 per DALY avoided, respectively. ML diagnostic tests based on PCR are cost-effective strategies, regardless of the level of clinical suspicion. PCR-kDNA was the most cost-effective strategy in the competitive scenario with the parameters included in the present model. Public Library of Science 2019-11-04 /pmc/articles/PMC6827906/ /pubmed/31682606 http://dx.doi.org/10.1371/journal.pone.0224351 Text en © 2019 Castillo-Rodríguez et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Castillo-Rodríguez, Liliana Ovalle-Bracho, Clemencia Díaz-Jiménez, Diana Sánchez-Vanegas, Guillermo Muvdi-Arenas, Sandra Castañeda-Orjuela, Carlos Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia |
title | Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia |
title_full | Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia |
title_fullStr | Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia |
title_full_unstemmed | Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia |
title_short | Cost-effectiveness analysis of Mucosal Leishmaniasis diagnosis with PCR-based vs parasitological tests in Colombia |
title_sort | cost-effectiveness analysis of mucosal leishmaniasis diagnosis with pcr-based vs parasitological tests in colombia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827906/ https://www.ncbi.nlm.nih.gov/pubmed/31682606 http://dx.doi.org/10.1371/journal.pone.0224351 |
work_keys_str_mv | AT castillorodriguezliliana costeffectivenessanalysisofmucosalleishmaniasisdiagnosiswithpcrbasedvsparasitologicaltestsincolombia AT ovallebrachoclemencia costeffectivenessanalysisofmucosalleishmaniasisdiagnosiswithpcrbasedvsparasitologicaltestsincolombia AT diazjimenezdiana costeffectivenessanalysisofmucosalleishmaniasisdiagnosiswithpcrbasedvsparasitologicaltestsincolombia AT sanchezvanegasguillermo costeffectivenessanalysisofmucosalleishmaniasisdiagnosiswithpcrbasedvsparasitologicaltestsincolombia AT muvdiarenassandra costeffectivenessanalysisofmucosalleishmaniasisdiagnosiswithpcrbasedvsparasitologicaltestsincolombia AT castanedaorjuelacarlos costeffectivenessanalysisofmucosalleishmaniasisdiagnosiswithpcrbasedvsparasitologicaltestsincolombia |